Rachel K. King
Director · 2 filings · Latest: Jun 30, 2026
Fulcrum Therapeutics, Inc.
NOVAVAX INC
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|
NVAX | Rachel K. King | Director | Jun 20, 2026 | Option Exercise | — | 18,880 | — | 44,070 | |
NVAX | Rachel K. King | — | Dec 13, 2024 | Proposed Sale | $9.00 | 4,150 | $37.4K | — | |